Emerging Therapies & Clinical Trial Opportunities for ER-Positive, HER2 Negative Metastatic Breast Cancer and HER2-Positive Breast Cancer

By December 2, 2016CME
Emerging Therapies & Clinical Trial Opportunities for ER-Positive, HER2 Negative Metastatic Breast Cancer and HER2-Positive Breast Cancer

Emerging Therapies & Clinical Trial Opportunities for ER-Positive, HER2 Negative Metastatic Breast Cancer and HER2-Positive Breast Cancer

Release Date: November 21, 2016 
Expiration Date:
 November 20, 2017

ESTIMATED TIME TO COMPLETE ACTIVITY:

1.5 hours (0.5 per module)

Take Pre-Test Download Module 1 (PDF)  Download Module 2 (PDF)  Download Module 3 (PDF)    Take Post-test

TARGET AUDIENCE

The target audience for these activities includes community- based medical oncologists, physician assistants, nurse practitioners, clinical nurse specialists, oncology nurses, nurse navigators, palliative/symptom management physicians and/or nurses, and other multidisciplinary members of the cancer care team caring for patients with ER-positive, metastatic breast cancer.

EDUCATIONAL OBJECTIVES

At the conclusion of these educational initiatives, participants should be able to:

Hal Burstein

  • Describe the mechanism of action of new agents for ER-positive, HER2-negative metastatic breast cancer
  • Recognize the evolving evidence for new agents for ER- positive, HER2-negative metastatic breast cancer
  • Identify clinical trial opportunities for ER-positive, HER2- negative metastatic breast cancer
  • Screen and educate breast cancer patients about clinical trial opportunities for which they are eligible

Joyce O’Shaughnessy, MD

  • Describe the mechanism of action of new agents for triple negative metastatic breast cancer
  • Recognize the evolving evidence for new agents for triple negative metastatic breast cancer
  • Identify clinical trial opportunities for triple negative metastatic breast cancer
  • Screen and educate breast cancer patients about clinical trial opportunities for which they are eligible

Carlos Arteaga, MD

  • Describe the mechanism of action of new agents for HER2-positive breast cancer
  • Recognize the evolving evidence for new agents for HER2- positive breast cancer
  • Identify clinical trial opportunities for HER2-positive breast cancer
  • Screen and educate breast cancer patients about clinical trial opportunities for which they are eligible

CHAIR

Hal Burstein, MD
Dana Farber Cancer Institute

FACULTY

Joyce O’Shaughnessy, MD
Baylor-Sammons Cancer Center

Carlos Arteaga, MD
Vanderbilt-Ingram Cancer Center

PHYSICIAN CONTINUING MEDICAL EDUCATION

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Carevive Systems, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ (0.5 per module). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING MEDICAL EDUCATION

Credit Designation

This educational activity for 1.5 contact hours (0.5 per module) is provided by Postgraduate Institute for Medicine.  Designated for 1.5 contact hours (0.5 per module) of pharmacotherapy credit for Advance Practice Registered Nurses.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related material that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Disclosures:

  • Hal Burstein, MD has no real or apparent con icts of interest to report.
  • Joyce O’Shaughnessy, MD; Consulting Fees, Aztrazeneca, Abb Vie, Celgene, Lilly, Novartis, P zer.
  • Carlos Arteaga, MD; Consulting Fees, Astrazeneca, Bayer, Clovis, Kiyatek, LabCorp, Lilly, Merrimack, Novartis, Provista, Radius, Roche, Symphogen; Contracted Research, Novartis, PUMA Biotechnology, Symphogen; Ownership Interest, Provista.

The planners and managers reported the following nancial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Judi Smelker- Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any nancial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following Carevive Systems, Inc. planners and managers reported the following: Timothy J. DiChiara, PhD, Consulting Fees, Gilead Sciences.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT

There are no fees for participating and receiving CME credit for this activity.

During the period November 21, 2016 through November 20, 2017 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 11356. Upon registering and successfully completing the post- test with a score of 50% or better and the activity evaluation, your certi cate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

MEDIA

e-Monograph

HARDWARE AND SOFTWARE REQUIREMENTS

CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/ or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the of cial prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Take Pre-Test Download Module 1 (PDF)  Download Module 2 (PDF)  Download Module 3 (PDF)    Take Post-test

Jointly provided by Postgraduate Institute for Medicine and Carevive Health, Inc.

Jointly provided by Postgraduate Institute for Medicine and Carevive Systems, Inc.

This activity is supported by an independent educational grant from Genentech BioOncology. Activity ID: G-407

Carevive Systems
Carevive Health is a clinician-led company with a scientifically rigorous and state-of-the-art care planning system used at the point of care to drive quality and improve patient outcomes. Sign up for our newsletter here.